Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-10-01
|
| Series: | Neurology and Therapy |
| Online Access: | https://doi.org/10.1007/s40120-023-00554-w |
| _version_ | 1797629928483586048 |
|---|---|
| author | Jason Aldred Eric Freire-Alvarez Alexander V. Amelin Angelo Antonini Bruno Bergmans Filip Bergquist Manon Bouchard Kumar Budur Camille Carroll K. Ray Chaudhuri Susan R. Criswell Erik H. Danielsen Florin Gandor Jia Jia Thomas E. Kimber Hideki Mochizuki Weining Z. Robieson Amy M. Spiegel David G. Standaert Saritha Talapala Maurizio F. Facheris Victor S. C. Fung |
| author_facet | Jason Aldred Eric Freire-Alvarez Alexander V. Amelin Angelo Antonini Bruno Bergmans Filip Bergquist Manon Bouchard Kumar Budur Camille Carroll K. Ray Chaudhuri Susan R. Criswell Erik H. Danielsen Florin Gandor Jia Jia Thomas E. Kimber Hideki Mochizuki Weining Z. Robieson Amy M. Spiegel David G. Standaert Saritha Talapala Maurizio F. Facheris Victor S. C. Fung |
| author_sort | Jason Aldred |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:00:45Z |
| format | Article |
| id | doaj.art-fbd221fdae034683822ddee813fd4949 |
| institution | Directory Open Access Journal |
| issn | 2193-8253 2193-6536 |
| language | English |
| last_indexed | 2024-03-11T11:00:45Z |
| publishDate | 2023-10-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj.art-fbd221fdae034683822ddee813fd49492023-11-12T12:34:20ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362023-10-011261959196010.1007/s40120-023-00554-wCorrection: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred0Eric Freire-Alvarez1Alexander V. Amelin2Angelo Antonini3Bruno Bergmans4Filip Bergquist5Manon Bouchard6Kumar Budur7Camille Carroll8K. Ray Chaudhuri9Susan R. Criswell10Erik H. Danielsen11Florin Gandor12Jia Jia13Thomas E. Kimber14Hideki Mochizuki15Weining Z. Robieson16Amy M. Spiegel17David G. Standaert18Saritha Talapala19Maurizio F. Facheris20Victor S. C. Fung21Selkirk Neurology and Inland Northwest ResearchNeurology Department, University General Hospital of ElcheDepartment of Neurology and Neurosurgery, Pavlov First Saint Petersburg State Medical UniversityParkinson and Movement Disorders Unit, Department of Neuroscience, Padua UniversityDepartment of Neurology, AZ St-Jan Brugge-Oostende AVDepartment of Pharmacology, University of GothenburgClinique Neuro-LévisAbbVie Inc.Faculty of Health, University of PlymouthParkinson’s Foundation International Centre of Excellence, King’s College HospitalDepartment of Neurology, Washington University in St. LouisDepartment of Neurology, Aarhus University HospitalMovement Disorders HospitalAbbVie Inc.Department of Neurology, Royal Adelaide HospitalDepartment of Neurology, Osaka University Graduate School of MedicineAbbVie Inc.AbbVie Inc.Department of Neurology, Heersink School of Medicine, University of Alabama at BirminghamAbbVie Inc.AbbVie Inc.Movement Disorders Unit, Westmead Hospitalhttps://doi.org/10.1007/s40120-023-00554-w |
| spellingShingle | Jason Aldred Eric Freire-Alvarez Alexander V. Amelin Angelo Antonini Bruno Bergmans Filip Bergquist Manon Bouchard Kumar Budur Camille Carroll K. Ray Chaudhuri Susan R. Criswell Erik H. Danielsen Florin Gandor Jia Jia Thomas E. Kimber Hideki Mochizuki Weining Z. Robieson Amy M. Spiegel David G. Standaert Saritha Talapala Maurizio F. Facheris Victor S. C. Fung Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Neurology and Therapy |
| title | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_full | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_fullStr | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_full_unstemmed | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_short | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_sort | correction continuous subcutaneous foslevodopa foscarbidopa in parkinson s disease safety and efficacy results from a 12 month single arm open label phase 3 study |
| url | https://doi.org/10.1007/s40120-023-00554-w |
| work_keys_str_mv | AT jasonaldred correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT ericfreirealvarez correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT alexandervamelin correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT angeloantonini correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT brunobergmans correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT filipbergquist correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT manonbouchard correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT kumarbudur correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT camillecarroll correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT kraychaudhuri correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT susanrcriswell correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT erikhdanielsen correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT floringandor correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT jiajia correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT thomasekimber correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT hidekimochizuki correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT weiningzrobieson correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT amymspiegel correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT davidgstandaert correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT sarithatalapala correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT maurizioffacheris correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT victorscfung correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study |